Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Rectal Neoplasms | 19 | 2023 | 1157 | 2.560 |
Why?
|
Esophageal Neoplasms | 19 | 2022 | 1654 | 2.430 |
Why?
|
Neoadjuvant Therapy | 23 | 2023 | 2827 | 1.870 |
Why?
|
Adenocarcinoma | 26 | 2023 | 6346 | 1.840 |
Why?
|
Stomach Neoplasms | 13 | 2023 | 1459 | 1.370 |
Why?
|
Fluorouracil | 18 | 2023 | 1641 | 1.320 |
Why?
|
Esophagectomy | 8 | 2021 | 468 | 1.310 |
Why?
|
Chemotherapy, Adjuvant | 16 | 2023 | 3514 | 1.310 |
Why?
|
Esophagogastric Junction | 6 | 2017 | 347 | 1.060 |
Why?
|
Pancreatic Neoplasms | 18 | 2023 | 5368 | 0.930 |
Why?
|
Gastrectomy | 6 | 2021 | 672 | 0.870 |
Why?
|
Neoplasm Staging | 26 | 2023 | 11121 | 0.710 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 20 | 2023 | 11742 | 0.690 |
Why?
|
Carcinoma, Squamous Cell | 7 | 2021 | 4026 | 0.660 |
Why?
|
Fluorodeoxyglucose F18 | 4 | 2018 | 2010 | 0.610 |
Why?
|
Neoplasm Recurrence, Local | 13 | 2023 | 9280 | 0.600 |
Why?
|
Anal Canal | 5 | 2023 | 373 | 0.600 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 10 | 2023 | 1661 | 0.550 |
Why?
|
Peritoneum | 1 | 2017 | 225 | 0.530 |
Why?
|
Deoxycytidine | 6 | 2014 | 877 | 0.530 |
Why?
|
Particle Accelerators | 3 | 2021 | 174 | 0.530 |
Why?
|
Radiotherapy Dosage | 12 | 2023 | 2898 | 0.520 |
Why?
|
Stereotaxic Techniques | 2 | 2008 | 555 | 0.500 |
Why?
|
Anus Neoplasms | 4 | 2022 | 329 | 0.480 |
Why?
|
Antimetabolites, Antineoplastic | 3 | 2014 | 646 | 0.480 |
Why?
|
Radiotherapy, Adjuvant | 6 | 2020 | 1784 | 0.470 |
Why?
|
Neoplasms, Second Primary | 1 | 2022 | 1052 | 0.470 |
Why?
|
Ossification, Heterotopic | 2 | 2007 | 235 | 0.460 |
Why?
|
Endpoint Determination | 1 | 2016 | 590 | 0.450 |
Why?
|
Liver Neoplasms | 7 | 2024 | 4320 | 0.380 |
Why?
|
Combined Modality Therapy | 17 | 2021 | 8529 | 0.380 |
Why?
|
Radiotherapy, Intensity-Modulated | 5 | 2022 | 801 | 0.380 |
Why?
|
Radiopharmaceuticals | 3 | 2018 | 2651 | 0.380 |
Why?
|
Disease-Free Survival | 12 | 2023 | 6814 | 0.370 |
Why?
|
Polymerase Chain Reaction | 9 | 2018 | 6075 | 0.350 |
Why?
|
Rectum | 2 | 2015 | 892 | 0.350 |
Why?
|
Leucovorin | 5 | 2023 | 643 | 0.340 |
Why?
|
Patient Preference | 1 | 2017 | 924 | 0.330 |
Why?
|
Radiosurgery | 4 | 2023 | 1342 | 0.320 |
Why?
|
Radiotherapy, Conformal | 5 | 2022 | 548 | 0.320 |
Why?
|
DNA Mutational Analysis | 6 | 2016 | 4111 | 0.310 |
Why?
|
Cisplatin | 5 | 2021 | 1651 | 0.280 |
Why?
|
Research Design | 4 | 2024 | 6180 | 0.270 |
Why?
|
Radiometry | 2 | 2009 | 813 | 0.270 |
Why?
|
DNA | 7 | 2018 | 7212 | 0.260 |
Why?
|
CA-19-9 Antigen | 3 | 2017 | 106 | 0.260 |
Why?
|
Microsatellite Instability | 2 | 2021 | 716 | 0.260 |
Why?
|
Humans | 114 | 2024 | 761504 | 0.260 |
Why?
|
Laparoscopy | 1 | 2017 | 2035 | 0.250 |
Why?
|
Proto-Oncogene Proteins | 12 | 2014 | 4511 | 0.250 |
Why?
|
Neoplasms | 9 | 2017 | 22170 | 0.250 |
Why?
|
Carcinoma, Pancreatic Ductal | 4 | 2020 | 1727 | 0.250 |
Why?
|
Tumor Burden | 6 | 2018 | 1893 | 0.240 |
Why?
|
Aged | 45 | 2023 | 169289 | 0.230 |
Why?
|
Gene Amplification | 1 | 2008 | 1089 | 0.220 |
Why?
|
Hip Prosthesis | 2 | 2007 | 921 | 0.220 |
Why?
|
Gold | 1 | 2007 | 482 | 0.220 |
Why?
|
Male | 64 | 2024 | 360804 | 0.220 |
Why?
|
Colostomy | 1 | 2003 | 105 | 0.220 |
Why?
|
Thoracic Neoplasms | 2 | 2020 | 267 | 0.220 |
Why?
|
Clinical Trials as Topic | 3 | 2024 | 8002 | 0.220 |
Why?
|
Radiation Protection | 1 | 2007 | 424 | 0.210 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2022 | 5315 | 0.210 |
Why?
|
Preoperative Care | 4 | 2023 | 2242 | 0.210 |
Why?
|
Aged, 80 and over | 25 | 2022 | 58976 | 0.200 |
Why?
|
G1 Phase | 1 | 2003 | 403 | 0.200 |
Why?
|
Positron-Emission Tomography | 5 | 2016 | 6485 | 0.200 |
Why?
|
Granuloma, Foreign-Body | 1 | 2021 | 42 | 0.190 |
Why?
|
Carboplatin | 3 | 2022 | 794 | 0.190 |
Why?
|
Female | 58 | 2024 | 392644 | 0.190 |
Why?
|
Comparative Effectiveness Research | 2 | 2024 | 709 | 0.190 |
Why?
|
Appendiceal Neoplasms | 1 | 2023 | 155 | 0.190 |
Why?
|
Preoperative Period | 1 | 2023 | 551 | 0.180 |
Why?
|
Middle Aged | 42 | 2024 | 220895 | 0.180 |
Why?
|
DNA, Neoplasm | 6 | 2023 | 1745 | 0.180 |
Why?
|
Prostheses and Implants | 1 | 2007 | 1271 | 0.180 |
Why?
|
Nucleic Acid Amplification Techniques | 3 | 2008 | 330 | 0.180 |
Why?
|
Lung Neoplasms | 8 | 2024 | 13380 | 0.170 |
Why?
|
Keratins | 1 | 2021 | 498 | 0.170 |
Why?
|
Retrospective Studies | 24 | 2023 | 80636 | 0.170 |
Why?
|
Camptothecin | 4 | 2017 | 591 | 0.170 |
Why?
|
Radiotherapy | 4 | 2017 | 1499 | 0.170 |
Why?
|
Brachytherapy | 1 | 2007 | 1223 | 0.170 |
Why?
|
Radiation Injuries | 5 | 2017 | 1189 | 0.170 |
Why?
|
Cholangiocarcinoma | 2 | 2015 | 552 | 0.160 |
Why?
|
Radiation Oncology | 3 | 2015 | 563 | 0.160 |
Why?
|
Bile Duct Neoplasms | 2 | 2015 | 605 | 0.160 |
Why?
|
Tomography, X-Ray Computed | 9 | 2016 | 20570 | 0.160 |
Why?
|
Radiotherapy, Computer-Assisted | 2 | 2009 | 90 | 0.160 |
Why?
|
Colectomy | 1 | 2003 | 688 | 0.150 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 6 | 2014 | 1745 | 0.150 |
Why?
|
Survival Rate | 9 | 2021 | 12725 | 0.150 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2019 | 117 | 0.150 |
Why?
|
Carcinoma, Hepatocellular | 3 | 2015 | 2298 | 0.150 |
Why?
|
Carcinoma, Adenoid Cystic | 1 | 2020 | 262 | 0.150 |
Why?
|
Nucleic Acid Denaturation | 3 | 2015 | 110 | 0.150 |
Why?
|
Treatment Outcome | 16 | 2023 | 64680 | 0.140 |
Why?
|
Colorectal Neoplasms | 4 | 2024 | 6935 | 0.140 |
Why?
|
Paclitaxel | 3 | 2022 | 1732 | 0.140 |
Why?
|
Dose-Response Relationship, Radiation | 3 | 2013 | 882 | 0.140 |
Why?
|
Chromosome Aberrations | 1 | 2003 | 1768 | 0.140 |
Why?
|
BRCA1 Protein | 1 | 2003 | 1155 | 0.140 |
Why?
|
Peritoneal Neoplasms | 1 | 2023 | 711 | 0.140 |
Why?
|
Neoplasm Metastasis | 6 | 2024 | 4915 | 0.140 |
Why?
|
Fractional Flow Reserve, Myocardial | 1 | 2020 | 323 | 0.130 |
Why?
|
Lymphatic Metastasis | 6 | 2021 | 2915 | 0.130 |
Why?
|
Drug Eruptions | 1 | 1999 | 335 | 0.130 |
Why?
|
Deglutition Disorders | 3 | 2017 | 625 | 0.130 |
Why?
|
Survival Analysis | 5 | 2020 | 10090 | 0.120 |
Why?
|
Digestive System Surgical Procedures | 1 | 2020 | 572 | 0.120 |
Why?
|
Patient Care | 1 | 2021 | 622 | 0.120 |
Why?
|
Adult | 22 | 2023 | 221177 | 0.120 |
Why?
|
Clinical Protocols | 1 | 2021 | 1440 | 0.120 |
Why?
|
ras Proteins | 5 | 2014 | 1054 | 0.120 |
Why?
|
Epirubicin | 3 | 2021 | 81 | 0.120 |
Why?
|
Myocardial Perfusion Imaging | 1 | 2020 | 575 | 0.120 |
Why?
|
Risk Factors | 10 | 2022 | 74206 | 0.120 |
Why?
|
Kaplan-Meier Estimate | 4 | 2019 | 6484 | 0.120 |
Why?
|
Antineoplastic Agents | 5 | 2017 | 13639 | 0.120 |
Why?
|
Alleles | 2 | 2016 | 6863 | 0.120 |
Why?
|
Treatment Failure | 3 | 2017 | 2645 | 0.120 |
Why?
|
Medical Illustration | 1 | 2015 | 135 | 0.120 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2016 | 321 | 0.120 |
Why?
|
Blue Cross Blue Shield Insurance Plans | 1 | 2014 | 92 | 0.110 |
Why?
|
Endonucleases | 1 | 2016 | 371 | 0.110 |
Why?
|
Cytodiagnosis | 1 | 2017 | 447 | 0.110 |
Why?
|
Perioperative Care | 1 | 2001 | 1033 | 0.110 |
Why?
|
Organs at Risk | 1 | 2015 | 359 | 0.100 |
Why?
|
Colonic Neoplasms | 3 | 2018 | 2538 | 0.100 |
Why?
|
Digestive System | 1 | 2013 | 244 | 0.100 |
Why?
|
Gastrointestinal Diseases | 2 | 2012 | 1200 | 0.100 |
Why?
|
Receptor, erbB-2 | 2 | 2022 | 2557 | 0.100 |
Why?
|
Apoptosis | 1 | 2008 | 9486 | 0.100 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 899 | 0.100 |
Why?
|
Risk Assessment | 6 | 2021 | 23995 | 0.100 |
Why?
|
Radiation Dosage | 4 | 2017 | 1958 | 0.100 |
Why?
|
Mutation | 9 | 2017 | 30052 | 0.100 |
Why?
|
Brain Neoplasms | 3 | 2012 | 9031 | 0.100 |
Why?
|
Portal Vein | 1 | 2014 | 431 | 0.100 |
Why?
|
Time Factors | 7 | 2021 | 39967 | 0.090 |
Why?
|
Insurance Carriers | 1 | 2013 | 156 | 0.090 |
Why?
|
Temperature | 3 | 2012 | 2226 | 0.090 |
Why?
|
Remission Induction | 1 | 2016 | 2396 | 0.090 |
Why?
|
Prognosis | 10 | 2019 | 29625 | 0.090 |
Why?
|
Movement | 2 | 2008 | 1478 | 0.090 |
Why?
|
Feasibility Studies | 6 | 2015 | 5247 | 0.090 |
Why?
|
Consensus | 3 | 2015 | 3123 | 0.090 |
Why?
|
Cancer Care Facilities | 1 | 2013 | 422 | 0.090 |
Why?
|
Hydroxychloroquine | 1 | 2014 | 426 | 0.090 |
Why?
|
X-Ray Intensifying Screens | 1 | 2009 | 32 | 0.090 |
Why?
|
Sequence Analysis, DNA | 1 | 2021 | 4740 | 0.080 |
Why?
|
Photons | 1 | 2013 | 589 | 0.080 |
Why?
|
Anticonvulsants | 1 | 1999 | 1906 | 0.080 |
Why?
|
Coronary Vessels | 1 | 2020 | 3096 | 0.080 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2011 | 350 | 0.080 |
Why?
|
Nuclear Proteins | 1 | 2003 | 5796 | 0.080 |
Why?
|
Keratosis, Seborrheic | 1 | 2008 | 27 | 0.080 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 3639 | 0.080 |
Why?
|
Prospective Studies | 9 | 2022 | 54425 | 0.080 |
Why?
|
Intestine, Small | 2 | 2012 | 1206 | 0.080 |
Why?
|
Follow-Up Studies | 7 | 2019 | 39106 | 0.080 |
Why?
|
Carcinoma, Signet Ring Cell | 1 | 2008 | 82 | 0.070 |
Why?
|
Lung | 2 | 2022 | 10000 | 0.070 |
Why?
|
Disease Progression | 3 | 2017 | 13506 | 0.070 |
Why?
|
Physical Phenomena | 1 | 2007 | 48 | 0.070 |
Why?
|
Prevalence | 2 | 2022 | 15732 | 0.070 |
Why?
|
Pilot Projects | 2 | 2018 | 8631 | 0.070 |
Why?
|
Algorithms | 6 | 2021 | 14031 | 0.070 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2003 | 8547 | 0.070 |
Why?
|
Physics | 1 | 2007 | 91 | 0.070 |
Why?
|
Technology, Radiologic | 1 | 2007 | 160 | 0.070 |
Why?
|
Heart | 1 | 2020 | 4404 | 0.070 |
Why?
|
Oligonucleotide Probes | 2 | 2018 | 416 | 0.070 |
Why?
|
DNA Fragmentation | 1 | 2007 | 237 | 0.070 |
Why?
|
Respiration | 1 | 2013 | 1657 | 0.070 |
Why?
|
Genome, Human | 3 | 2016 | 4425 | 0.070 |
Why?
|
Multivariate Analysis | 2 | 2014 | 12059 | 0.070 |
Why?
|
Breast Neoplasms | 4 | 2021 | 21012 | 0.070 |
Why?
|
Phantoms, Imaging | 2 | 2021 | 2526 | 0.070 |
Why?
|
Reproducibility of Results | 7 | 2020 | 20098 | 0.070 |
Why?
|
Infrared Rays | 1 | 2008 | 247 | 0.070 |
Why?
|
Biopsy | 1 | 2018 | 6766 | 0.070 |
Why?
|
Automation | 1 | 2008 | 586 | 0.070 |
Why?
|
Autophagy | 1 | 2014 | 1326 | 0.070 |
Why?
|
Arthroplasty, Replacement, Hip | 2 | 2007 | 1413 | 0.070 |
Why?
|
Indomethacin | 1 | 2006 | 325 | 0.060 |
Why?
|
Cell Cycle | 2 | 1991 | 2932 | 0.060 |
Why?
|
Allelic Imbalance | 1 | 2006 | 77 | 0.060 |
Why?
|
Patient Selection | 4 | 2015 | 4244 | 0.060 |
Why?
|
Cell Line, Tumor | 6 | 2018 | 16981 | 0.060 |
Why?
|
Radiography | 4 | 2010 | 6965 | 0.060 |
Why?
|
Venous Thrombosis | 1 | 2014 | 1303 | 0.060 |
Why?
|
Nausea | 3 | 2016 | 679 | 0.060 |
Why?
|
Carcinoma | 1 | 2016 | 2330 | 0.060 |
Why?
|
SEER Program | 3 | 2018 | 1450 | 0.060 |
Why?
|
Tomography, Emission-Computed | 1 | 2007 | 1122 | 0.060 |
Why?
|
Cold Temperature | 1 | 2008 | 785 | 0.060 |
Why?
|
Nurses | 1 | 2013 | 2478 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2021 | 10209 | 0.060 |
Why?
|
Epilepsy | 1 | 1999 | 3290 | 0.050 |
Why?
|
Electronic Health Records | 1 | 2020 | 4811 | 0.050 |
Why?
|
Patient Readmission | 1 | 2017 | 3270 | 0.050 |
Why?
|
Analysis of Variance | 2 | 2013 | 6228 | 0.050 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2008 | 710 | 0.050 |
Why?
|
Oligonucleotides | 1 | 2006 | 582 | 0.050 |
Why?
|
Organoplatinum Compounds | 2 | 2019 | 407 | 0.050 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2009 | 1222 | 0.050 |
Why?
|
Radiography, Abdominal | 1 | 2005 | 534 | 0.050 |
Why?
|
Palliative Care | 2 | 2015 | 3598 | 0.050 |
Why?
|
Lung Injury | 1 | 2007 | 422 | 0.050 |
Why?
|
Tumor Suppressor Protein p53 | 4 | 2015 | 2917 | 0.050 |
Why?
|
Carcinoembryonic Antigen | 2 | 2014 | 337 | 0.050 |
Why?
|
Chromosomes, Human | 1 | 2003 | 441 | 0.050 |
Why?
|
DNA Primers | 1 | 2006 | 2819 | 0.050 |
Why?
|
Prosthesis Failure | 1 | 2007 | 1204 | 0.050 |
Why?
|
Medical Oncology | 1 | 2013 | 2321 | 0.050 |
Why?
|
Phosphorylation | 6 | 2003 | 8320 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2003 | 368 | 0.050 |
Why?
|
Fecal Incontinence | 1 | 2003 | 241 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-raf | 5 | 1994 | 205 | 0.050 |
Why?
|
Patient Participation | 1 | 2010 | 1444 | 0.050 |
Why?
|
Pandemics | 1 | 2021 | 8654 | 0.050 |
Why?
|
Pancreatectomy | 1 | 2005 | 811 | 0.050 |
Why?
|
Alu Elements | 1 | 2021 | 115 | 0.040 |
Why?
|
Neoplasm Invasiveness | 3 | 2015 | 3595 | 0.040 |
Why?
|
Erectile Dysfunction | 1 | 2003 | 444 | 0.040 |
Why?
|
Fiducial Markers | 1 | 2021 | 132 | 0.040 |
Why?
|
Anastomosis, Surgical | 1 | 2003 | 983 | 0.040 |
Why?
|
Limit of Detection | 1 | 2021 | 273 | 0.040 |
Why?
|
Proportional Hazards Models | 3 | 2021 | 12463 | 0.040 |
Why?
|
Spleen | 1 | 2005 | 2295 | 0.040 |
Why?
|
Lymph Nodes | 2 | 2015 | 3466 | 0.040 |
Why?
|
Erythema Multiforme | 1 | 1999 | 31 | 0.040 |
Why?
|
Radiodermatitis | 1 | 1999 | 60 | 0.040 |
Why?
|
Sensitivity and Specificity | 5 | 2016 | 14666 | 0.040 |
Why?
|
Pancreaticoduodenectomy | 2 | 2014 | 509 | 0.040 |
Why?
|
Electrophoresis, Capillary | 1 | 2018 | 63 | 0.040 |
Why?
|
Phenytoin | 1 | 1999 | 190 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2021 | 11118 | 0.040 |
Why?
|
Quality of Life | 4 | 2023 | 13367 | 0.040 |
Why?
|
Fluorescent Dyes | 1 | 2006 | 1903 | 0.040 |
Why?
|
INDEL Mutation | 1 | 2018 | 266 | 0.040 |
Why?
|
Standard of Care | 1 | 2021 | 551 | 0.040 |
Why?
|
Salvage Therapy | 1 | 2003 | 1264 | 0.030 |
Why?
|
Heartburn | 1 | 2017 | 68 | 0.030 |
Why?
|
Cell Line | 6 | 2021 | 15601 | 0.030 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2008 | 2020 | 0.030 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 2273 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2019 | 629 | 0.030 |
Why?
|
Imaging, Three-Dimensional | 1 | 2009 | 4063 | 0.030 |
Why?
|
Tumor Escape | 1 | 2019 | 370 | 0.030 |
Why?
|
Anorexia | 1 | 2016 | 154 | 0.030 |
Why?
|
Proto-Oncogenes | 3 | 1991 | 321 | 0.030 |
Why?
|
Mediastinum | 1 | 2017 | 267 | 0.030 |
Why?
|
Physicians | 1 | 2013 | 4591 | 0.030 |
Why?
|
Quality of Health Care | 3 | 2017 | 4330 | 0.030 |
Why?
|
Young Adult | 3 | 2017 | 59243 | 0.030 |
Why?
|
Formaldehyde | 2 | 2007 | 358 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2019 | 857 | 0.030 |
Why?
|
Administration, Oral | 2 | 2016 | 4021 | 0.030 |
Why?
|
Astrocytoma | 1 | 1999 | 775 | 0.030 |
Why?
|
Radiation Tolerance | 1 | 2016 | 479 | 0.030 |
Why?
|
Diarrhea | 2 | 2012 | 1318 | 0.030 |
Why?
|
Receptors, CXCR | 1 | 2014 | 52 | 0.030 |
Why?
|
DNA Repair | 1 | 2003 | 2045 | 0.030 |
Why?
|
Lymphatic System | 1 | 2015 | 254 | 0.030 |
Why?
|
Data Interpretation, Statistical | 1 | 2024 | 2691 | 0.030 |
Why?
|
Age Factors | 3 | 2021 | 18395 | 0.030 |
Why?
|
Protein Kinases | 2 | 1991 | 1608 | 0.030 |
Why?
|
Recombinant Proteins | 1 | 2003 | 6534 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2019 | 1702 | 0.030 |
Why?
|
Infection Control | 1 | 2021 | 981 | 0.030 |
Why?
|
DNA Damage | 1 | 2003 | 2446 | 0.030 |
Why?
|
Kidney | 2 | 2007 | 7048 | 0.030 |
Why?
|
Cell Survival | 1 | 2003 | 5791 | 0.030 |
Why?
|
Tyrosine 3-Monooxygenase | 1 | 1994 | 370 | 0.030 |
Why?
|
Tumor Suppressor Proteins | 1 | 2003 | 2803 | 0.030 |
Why?
|
Delphi Technique | 1 | 2017 | 846 | 0.030 |
Why?
|
Adenomatous Polyposis Coli Protein | 1 | 2014 | 181 | 0.030 |
Why?
|
Liver | 2 | 2007 | 7529 | 0.030 |
Why?
|
Length of Stay | 2 | 2021 | 6425 | 0.030 |
Why?
|
Tumor Virus Infections | 1 | 2015 | 438 | 0.030 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2023 | 3769 | 0.030 |
Why?
|
Hepatocyte Growth Factor | 1 | 2014 | 270 | 0.030 |
Why?
|
Genotype | 3 | 2017 | 12990 | 0.030 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2019 | 1349 | 0.030 |
Why?
|
Intestine, Large | 1 | 2012 | 68 | 0.030 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2013 | 296 | 0.030 |
Why?
|
Cell Cycle Proteins | 1 | 2003 | 3448 | 0.020 |
Why?
|
Proton Pump Inhibitors | 1 | 2017 | 532 | 0.020 |
Why?
|
Genes, ras | 1 | 2014 | 654 | 0.020 |
Why?
|
Enzyme Activation | 3 | 1994 | 3597 | 0.020 |
Why?
|
Workflow | 1 | 2016 | 851 | 0.020 |
Why?
|
Focus Groups | 1 | 2017 | 1413 | 0.020 |
Why?
|
Oncogene Protein pp60(v-src) | 1 | 1991 | 75 | 0.020 |
Why?
|
Blood Loss, Surgical | 1 | 2015 | 637 | 0.020 |
Why?
|
Neoplasm, Residual | 1 | 2016 | 1008 | 0.020 |
Why?
|
Stents | 1 | 2023 | 3179 | 0.020 |
Why?
|
Patient Compliance | 1 | 2021 | 2690 | 0.020 |
Why?
|
Polyomavirus | 1 | 1991 | 234 | 0.020 |
Why?
|
Defecation | 1 | 2012 | 190 | 0.020 |
Why?
|
International Cooperation | 1 | 2017 | 1422 | 0.020 |
Why?
|
GTP Phosphohydrolases | 1 | 2014 | 517 | 0.020 |
Why?
|
Health Care Costs | 2 | 2014 | 3242 | 0.020 |
Why?
|
Interphase | 1 | 1991 | 228 | 0.020 |
Why?
|
Genes, p53 | 1 | 2012 | 712 | 0.020 |
Why?
|
Massachusetts | 2 | 2014 | 8830 | 0.020 |
Why?
|
Freezing | 1 | 2011 | 311 | 0.020 |
Why?
|
Postoperative Complications | 2 | 2021 | 15631 | 0.020 |
Why?
|
Duodenal Neoplasms | 1 | 2010 | 114 | 0.020 |
Why?
|
Interleukin-3 | 1 | 1991 | 425 | 0.020 |
Why?
|
Artifacts | 1 | 2018 | 1911 | 0.020 |
Why?
|
Base Sequence | 3 | 2011 | 12441 | 0.020 |
Why?
|
Papillomaviridae | 1 | 2015 | 1119 | 0.020 |
Why?
|
Signal Transduction | 6 | 1994 | 23445 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2021 | 2811 | 0.020 |
Why?
|
Uncertainty | 1 | 2014 | 754 | 0.020 |
Why?
|
Neuroendocrine Tumors | 1 | 2015 | 641 | 0.020 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 1991 | 899 | 0.020 |
Why?
|
Microtubule-Associated Proteins | 1 | 2014 | 1076 | 0.020 |
Why?
|
Capsid | 1 | 1991 | 435 | 0.020 |
Why?
|
Failure to Thrive | 1 | 2009 | 140 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 1999 | 6310 | 0.020 |
Why?
|
Risk | 1 | 2021 | 9610 | 0.020 |
Why?
|
Reimbursement Mechanisms | 1 | 2014 | 667 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2016 | 4853 | 0.020 |
Why?
|
Cytarabine | 1 | 2010 | 697 | 0.020 |
Why?
|
Observer Variation | 1 | 2014 | 2606 | 0.020 |
Why?
|
Evolution, Molecular | 1 | 2016 | 1886 | 0.020 |
Why?
|
Molecular Sequence Data | 2 | 2011 | 17635 | 0.020 |
Why?
|
Recurrence | 1 | 2020 | 8465 | 0.020 |
Why?
|
Lymphoma | 1 | 2017 | 1901 | 0.020 |
Why?
|
Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2007 | 78 | 0.020 |
Why?
|
Prescriptions | 1 | 2010 | 386 | 0.020 |
Why?
|
Growth Substances | 1 | 1989 | 768 | 0.020 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1991 | 891 | 0.020 |
Why?
|
Quinazolines | 1 | 2014 | 1371 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2014 | 1505 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2021 | 3530 | 0.020 |
Why?
|
Radiology | 1 | 2021 | 2113 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2009 | 15842 | 0.020 |
Why?
|
Gastroscopy | 1 | 2008 | 211 | 0.020 |
Why?
|
Health Services Research | 1 | 2014 | 1812 | 0.020 |
Why?
|
Equipment Design | 1 | 2015 | 3510 | 0.020 |
Why?
|
Intraoperative Complications | 1 | 2013 | 1165 | 0.020 |
Why?
|
Tissue Fixation | 1 | 2007 | 241 | 0.020 |
Why?
|
Lymphocytes | 1 | 2014 | 2612 | 0.020 |
Why?
|
Fixatives | 1 | 2006 | 90 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2003 | 9606 | 0.020 |
Why?
|
Vomiting | 1 | 2009 | 651 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2019 | 3877 | 0.020 |
Why?
|
Antigens, Viral, Tumor | 1 | 1986 | 153 | 0.020 |
Why?
|
Simian virus 40 | 1 | 1986 | 291 | 0.020 |
Why?
|
Pain | 2 | 2012 | 5073 | 0.020 |
Why?
|
Protein-Tyrosine Kinases | 3 | 1991 | 2425 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 9420 | 0.020 |
Why?
|
Genes, Viral | 1 | 1986 | 649 | 0.020 |
Why?
|
Paraffin Embedding | 1 | 2006 | 302 | 0.020 |
Why?
|
Radiographic Image Enhancement | 1 | 2009 | 876 | 0.010 |
Why?
|
Oncogene Proteins, Viral | 1 | 1986 | 340 | 0.010 |
Why?
|
Apolipoproteins B | 1 | 2006 | 386 | 0.010 |
Why?
|
Interleukin-2 | 1 | 1991 | 1889 | 0.010 |
Why?
|
Postoperative Care | 1 | 2010 | 1468 | 0.010 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2014 | 2057 | 0.010 |
Why?
|
Oncogenes | 1 | 1989 | 1222 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2009 | 2850 | 0.010 |
Why?
|
Constipation | 1 | 2008 | 563 | 0.010 |
Why?
|
Papillomavirus Infections | 1 | 2015 | 1613 | 0.010 |
Why?
|
Microsatellite Repeats | 1 | 2006 | 784 | 0.010 |
Why?
|
Pattern Recognition, Automated | 1 | 2009 | 997 | 0.010 |
Why?
|
Stomach | 1 | 2007 | 696 | 0.010 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2010 | 1116 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2016 | 15936 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2007 | 2219 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2014 | 36426 | 0.010 |
Why?
|
Adolescent | 3 | 2014 | 88319 | 0.010 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2006 | 1541 | 0.010 |
Why?
|
Genes | 1 | 1986 | 1823 | 0.010 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 1991 | 2547 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2016 | 5305 | 0.010 |
Why?
|
Regression Analysis | 1 | 2010 | 6343 | 0.010 |
Why?
|
Antigens, CD | 1 | 1991 | 4003 | 0.010 |
Why?
|
Cell Transformation, Neoplastic | 2 | 1988 | 2825 | 0.010 |
Why?
|
Databases, Factual | 1 | 2015 | 7967 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2013 | 3889 | 0.010 |
Why?
|
Proteins | 1 | 1994 | 6032 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2011 | 3688 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2020 | 26125 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 1991 | 13446 | 0.010 |
Why?
|
Tetradecanoylphorbol Acetate | 2 | 1991 | 817 | 0.010 |
Why?
|
Models, Biological | 2 | 1991 | 9469 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 1991 | 7594 | 0.010 |
Why?
|
Ultrasonography | 1 | 2010 | 5972 | 0.010 |
Why?
|
Angiogenesis Inhibitors | 1 | 2007 | 2047 | 0.010 |
Why?
|
Glioblastoma | 1 | 2012 | 3482 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2014 | 7856 | 0.010 |
Why?
|
Weight Loss | 1 | 2008 | 2684 | 0.010 |
Why?
|
RNA, Messenger | 1 | 1991 | 12795 | 0.010 |
Why?
|
Animals | 6 | 2014 | 168459 | 0.010 |
Why?
|
Artificial Intelligence | 1 | 2009 | 2578 | 0.010 |
Why?
|
Comorbidity | 1 | 2009 | 10508 | 0.010 |
Why?
|
Spodoptera | 1 | 1994 | 141 | 0.010 |
Why?
|
Plasmids | 2 | 1991 | 2269 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 1991 | 10194 | 0.010 |
Why?
|
14-3-3 Proteins | 1 | 1994 | 220 | 0.010 |
Why?
|
3T3 Cells | 1 | 1994 | 1085 | 0.010 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 1994 | 426 | 0.010 |
Why?
|
Zinc Fingers | 1 | 1994 | 579 | 0.010 |
Why?
|
Mice | 3 | 2014 | 81525 | 0.010 |
Why?
|
Ionomycin | 1 | 1991 | 110 | 0.010 |
Why?
|
Moths | 1 | 1991 | 81 | 0.010 |
Why?
|
Baculoviridae | 1 | 1991 | 115 | 0.010 |
Why?
|
Receptors, Cell Surface | 2 | 1991 | 2822 | 0.010 |
Why?
|
Ethers, Cyclic | 1 | 1991 | 32 | 0.010 |
Why?
|
Okadaic Acid | 1 | 1991 | 67 | 0.010 |
Why?
|
Vanadates | 1 | 1991 | 82 | 0.010 |
Why?
|
Cyclosporins | 1 | 1991 | 216 | 0.010 |
Why?
|
Hospitalization | 1 | 2011 | 10723 | 0.010 |
Why?
|
Cycloheximide | 1 | 1991 | 343 | 0.010 |
Why?
|
Receptor, Macrophage Colony-Stimulating Factor | 1 | 1991 | 94 | 0.010 |
Why?
|
Phosphoserine | 1 | 1991 | 203 | 0.010 |
Why?
|
Receptors, Platelet-Derived Growth Factor | 1 | 1991 | 178 | 0.010 |
Why?
|
Precipitin Tests | 1 | 1991 | 814 | 0.010 |
Why?
|
S Phase | 1 | 1991 | 421 | 0.010 |
Why?
|
Blotting, Northern | 1 | 1991 | 1545 | 0.010 |
Why?
|
United States | 1 | 2017 | 72334 | 0.010 |
Why?
|
Macromolecular Substances | 1 | 1991 | 1434 | 0.000 |
Why?
|
Ovarian Neoplasms | 1 | 2006 | 4876 | 0.000 |
Why?
|
1-Phosphatidylinositol 4-Kinase | 1 | 1988 | 59 | 0.000 |
Why?
|
Capsid Proteins | 1 | 1991 | 468 | 0.000 |
Why?
|
Microscopy, Electron | 1 | 1991 | 2561 | 0.000 |
Why?
|
Peptide Mapping | 1 | 1988 | 262 | 0.000 |
Why?
|
Morphogenesis | 1 | 1991 | 741 | 0.000 |
Why?
|
Phosphotransferases | 1 | 1988 | 303 | 0.000 |
Why?
|
Cytoplasm | 1 | 1991 | 1510 | 0.000 |
Why?
|
Cloning, Molecular | 1 | 1991 | 4174 | 0.000 |
Why?
|
Binding Sites | 1 | 1994 | 6055 | 0.000 |
Why?
|
Platelet-Derived Growth Factor | 1 | 1988 | 618 | 0.000 |
Why?
|
Antigens, Polyomavirus Transforming | 1 | 1986 | 257 | 0.000 |
Why?
|
Mice, Inbred Strains | 1 | 1988 | 1762 | 0.000 |
Why?
|
Immunoblotting | 1 | 1988 | 1646 | 0.000 |
Why?
|
Cells, Cultured | 2 | 1991 | 18965 | 0.000 |
Why?
|
Blotting, Western | 1 | 1991 | 5035 | 0.000 |
Why?
|
Tyrosine | 1 | 1988 | 1440 | 0.000 |
Why?
|
Cell Nucleus | 1 | 1991 | 2909 | 0.000 |
Why?
|
Genetic Vectors | 1 | 1991 | 3395 | 0.000 |
Why?
|
Nerve Tissue Proteins | 1 | 1994 | 4414 | 0.000 |
Why?
|
RNA | 1 | 1991 | 2726 | 0.000 |
Why?
|
Gene Expression | 1 | 1991 | 7581 | 0.000 |
Why?
|
Gene Expression Regulation | 1 | 1988 | 11903 | 0.000 |
Why?
|